Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.

Pharmacogenetics - 1 Dec 2004

King Barry P, Khan Tayyaba I, Aithal Guruprasad P, Kamali Farhad, Daly Ann K

Abstract excerpt

OBJECTIVES: To assess whether CYP2C9 alleles other than CYP2C9*2 and *3 are associated with a low-warfarin dose requirement and the relevance of upstream CYP2C9 polymorphisms to dose requirement and metabolism. METHODS: CYP2C9 exons, intron-exon boundaries and 3 kb of upstream sequence in 20 patients requiring <or= 1.5 mg warfarin per day and with apparently homozygous wild-type or heterozygous CYP2C9*2 genotypes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Polymorphism, Restriction Fragment Length

Share to Polymorphism, Single-Stranded Conformational

Share to United Kingdom

Share to Warfarin

Share to White People

Source

Identifiers

PMID: 15608560
DOI: 10.1097/00008571-200412000-00004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.PMID 15608560Read ↗

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.Semantic proximity Read ↗

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.Semantic proximity Read ↗

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.Semantic proximity Read ↗

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Semantic proximity Read ↗

Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.Semantic proximity Read ↗

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.Semantic proximity Read ↗

The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.Semantic proximity Read ↗

Association of warfarin dose with genes involved in its action and metabolismSemantic proximity Read ↗

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.Semantic proximity Read ↗

Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy.Semantic proximity Read ↗

Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.Semantic proximity Read ↗

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.